Project Number 5R01AG061122-03 Agency/Funding Organization NIA Funding Year 2021 View Full Project Details for Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) j. Metabolism and Bioenergetics Researcher and Organization Principal Investigator DIDSBURY, JOHN Principal Investigator First Name JOHN Principal Investigator Last Name DIDSBURY Awardee Organization T3D THERAPEUTICS, INC. Awardee State North Carolina Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-18-175: Pilot Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) FY Overall Cost $5,526,539 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official RYAN, LAURIE M